Analysts have been eager to weigh in on the Healthcare sector with new ratings on Regeneron (REGN – Research Report) and Biofrontera (BFRI – Research Report).
Regeneron (REGN)
RBC Capital analyst Brian Abrahams maintained a Hold rating on Regeneron on July 7 and set a price target of $640.00. The company’s shares closed last Friday at $621.57.
According to TipRanks.com, Abrahams is a 1-star analyst with an average return of
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Regeneron with a $678.25 average price target.
See today’s best-performing stocks on TipRanks >>
Biofrontera (BFRI)
In a report issued on May 25, Jonathan Aschoff from Roth Capital reiterated a Buy rating on Biofrontera, with a price target of $20.00. The company’s shares closed last Friday at $1.78, close to its 52-week low of $1.75.
According to TipRanks.com, Aschoff is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on Biofrontera is a Moderate Buy with an average price target of $15.50, a 770.8% upside from current levels. In a report issued on June 3, Benchmark Co. also reiterated a Buy rating on the stock with a $11.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on REGN:
- Analysts Offer Insights on Materials Companies: and RPM International (RPM)
- Analysts Offer Insights on Materials Companies: Marathon Gold (OtherMGDPF) and Hecla Mining Company (HL)
- RBC Capital Sticks to Their Buy Rating for Precision Drilling (PDS)
- Netflix’s Content Juggernaut Makes it a Buy at Multiyear Lows
- Positive Initial Clinical Data from the B-LIEVE Dose-Confirmation Trial for FLT180a in Hemophilia B Presented at the International Society on Thrombosis and Haemostasis Congress
